ALGS - Aligos Therapeutics Inc. - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-62.67M

Cash

135.7M

Avg Qtr Burn

-19.75M

Short % of Float

1.79%

Insider Ownership

21.07%

Institutional Own.

62.53%

Qtr Updated

12/31/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ALG-055009 (THR-β Agonist) Details Non-alcoholic steatohepatitis	Phase 2a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ALG-000184 (Capsid Assembly modulator) Details Chronic hepatitis B	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ALG-097558 Details COVID-19	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ALG-010133 (S-antigen Transport-inhibiting Oligonucleotide Polymer) Details Chronic hepatitis B	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ALG-125755 Details Chronic hepatitis B, Liver disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.